BridgeBio Pharma Valuation
| BBIO Stock | USD 27.49 1.05 3.97% |
At this time, the firm appears to be undervalued. BridgeBio Pharma shows a prevailing Real Value of $34.58 per share. The current price of the firm is $27.49. Our model approximates the value of BridgeBio Pharma from analyzing the firm fundamentals such as Current Valuation of 6.46 B, profit margin of (2.02) %, and Return On Equity of -17.9 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BridgeBio Pharma's valuation include:
Price Book 123.6828 | Enterprise Value 6.5 B | Enterprise Value Ebitda (9.40) | Price Sales 22.9463 | Enterprise Value Revenue 29.6665 |
Undervalued
Today
Please note that BridgeBio Pharma's price fluctuation is not too volatile at this time. Calculation of the real value of BridgeBio Pharma is based on 3 months time horizon. Increasing BridgeBio Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BridgeBio Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BridgeBio Stock. However, BridgeBio Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.49 | Real 34.58 | Target 46.4 | Hype 27.25 | Naive 27.52 |
The intrinsic value of BridgeBio Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BridgeBio Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BridgeBio Pharma helps investors to forecast how BridgeBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BridgeBio Pharma more accurately as focusing exclusively on BridgeBio Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BridgeBio Pharma's intrinsic value based on its ongoing forecasts of BridgeBio Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BridgeBio Pharma's closest peers.
BridgeBio Pharma Cash |
|
BridgeBio Valuation Trend
Knowing BridgeBio Pharma's actual value is paramount for traders when making sound investment determinations. Using both BridgeBio Pharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
BridgeBio Pharma Total Value Analysis
BridgeBio Pharma is currently forecasted to have valuation of 6.46 B with market capitalization of 5 B, debt of 1.74 B, and cash on hands of 715.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BridgeBio Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.46 B | 5 B | 1.74 B | 715.71 M |
BridgeBio Pharma Investor Information
About 94.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.05. BridgeBio Pharma recorded a loss per share of 2.42. The entity had not issued any dividends in recent years. Based on the key measurements obtained from BridgeBio Pharma's financial statements, BridgeBio Pharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.BridgeBio Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BridgeBio Pharma has an asset utilization ratio of 1.7 percent. This suggests that the Company is making $0.017 for each dollar of assets. An increasing asset utilization means that BridgeBio Pharma is more efficient with each dollar of assets it utilizes for everyday operations.BridgeBio Pharma Ownership Allocation
BridgeBio Pharma holds a total of 188.99 Million outstanding shares. The majority of BridgeBio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BridgeBio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BridgeBio Pharma. Please pay attention to any change in the institutional holdings of BridgeBio Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BridgeBio Pharma Profitability Analysis
The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (643.2 M) with profit before overhead, payroll, taxes, and interest of 74.21 M.About BridgeBio Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of BridgeBio Pharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BridgeBio Pharma based exclusively on its fundamental and basic technical indicators. By analyzing BridgeBio Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of BridgeBio Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of BridgeBio Pharma. We calculate exposure to BridgeBio Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BridgeBio Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.9 M | 6.5 M | |
| Pretax Profit Margin | (70.22) | (66.71) | |
| Operating Profit Margin | (65.29) | (62.02) | |
| Net Loss | (69.14) | (65.68) | |
| Gross Profit Margin | 0.74 | 0.92 |
BridgeBio Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 162.8 M |
BridgeBio Pharma Current Valuation Indicators
BridgeBio Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final BridgeBio Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BridgeBio Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BridgeBio Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BridgeBio Pharma's worth.When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.